Amgen Pharma.

The other side.

In the company's conference room.

The extraordinary shareholders' meeting was quite intense, and the initial purpose of the meeting was to discuss the proportion of Abel Sefrossa's stake in Amgen Pharmaceutical.

Originally, 100 million US dollars was actually asked for 50% of the shares, and all the shareholders and President Binder himself were quite opposed.

They are very poor for money right now and need to invest very much. But it's not the turn to sell cabbage at the same price as the company.

But the details in the VAM contract.

But it made the shareholders start to move.

The company's new drugs and new patents, and the difficulty of the development of granulocyte bone marrow therapy agents, the whole company can be said to have a 10-point understanding.

Lin Fukun led the development of EPO, although it saved the company's life at the beginning. However, compared with granulocytes, EPO can only be regarded as a lifesaver in terms of significance and economic value to the company.

And once granulocytes can be successfully developed, it will be no less than Amgen Pharma has obtained a cash cow.

A lifesaver and a cash cow.

Although the former can save lives, it can't make everyone rich. Although the latter came relatively late, once it really grows up and matures, the cash cow can make everyone rich.

Which is more important.

Everybody knows about it.

Naturally, everyone is concerned about the difficulty of developing granulocytes, a new drug patent that has not been completely successful since the company's establishment and research and development.

It is precisely because of the knowledge of this difficulty.

Let the shareholders present, as well as Mr. President and the chairman of the board of directors who concentrated on conducting experiments under the command of Abel in the laboratory.

They would never believe that granulocyte research therapeutics could succeed so easily. Although it has actually been successful, it has the effect it deserves. It is the frequency of side effects, which are more severe. As a result, clinical trials that have not passed the last hurdle of the FDA.

If there are no side effects, and the FDA can pass the last clinical trial of more than 3,000 people, it will be able to be produced and marketed immediately next month.

Originally. According to the company's two scientific research leaders, Lin Fukun and George Lasman, predicted. As long as the company is well funded, it should be able to pass the FDA's final review as soon as this time next year, and then go to market quickly within two months.

Now the shareholders also have Gordon M. M. Binder himself was the same as George Lasman at the beginning.

I don't believe that the conditions mentioned in the gambling contract will be fulfilled.

Therefore, after everyone has read the details of the VAM contract, when Binder stands up and hopes that the shareholders and shareholder representatives will speak freely.

The shareholder representative of Crocker National Company stood up for the first time and said to everyone in a questioning tone, "I have read the contract. From the standpoint of Crocker National, I vote in favor of this VAM contract!"

After finishing speaking, the representative smiled again and said: "This young man is anxious about everyone's needs. He didn't really want much of a stake in the company at all, he just wanted to give us money! Why should we stop such a good thing? With this investment, Mr. Binder didn't have to run around anymore. We don't need to inject capital into the company anymore, and this money can at least last until the new drug is officially launched!

"But. Binder cautiously added, "In case the other side does succeed." Then his $100 million can be turned into at least 50% of the shares. And if it is studied within a week, it will be 50 million US dollars to get 55% of the shares and more than 80% of the voting rights. ”

"What? The Californian real estate tycoon also stood up, and he joked with a smile, "What do you mean by that, are you worried that the young man really succeeded in researching the research that Lin and George spent 10 years not being able to ?!! haha, if that's the case, then I'm also Einstein!"

A joke about this shareholder.

All of a sudden, the atmosphere of the meeting became relaxed, and everyone laughed together, and there was a lot of laughter.

Gordon S. M. Binder had to shrug his shoulders.

In fact, he didn't really believe that the conditions from the inside would really be realized.

Solve granulocyte problems in a week.

Oh, my God!

Even he, a graduate of Harvard Business School, knows that a person who graduated from chemistry and medicine needs to check the information if he wants to figure out some terms such as biomedicine.

How is it possible to solve one of the most difficult problems in the discipline of biomedicine in one week?

Binder would add cautiously.

It's just a simple dumping.

After all, he brought back the people, and he also brought the investment back. Even the conditions of this VAM contract were discussed with the other party, and then shown to the chairman of the board of directors, George Lassman, after knowing from the chairman of the scientist that scientific research problems could not be so easy to succeed.

It was the cautious Binder who brought the contract to the board of directors and put it in front of the shareholders and their representatives.

But.

Unlike the shareholders and shareholder representatives, who were laughing and laughing, Binder felt that Abel could not succeed. But in his own position, even if Abel succeeds, binder doesn't matter.

First of all, he is management.

And he manages the company very well, both inside and outside the company, and he has a high evaluation of himself. Now, as long as Amgen Pharma is not in his hands, he can choose a similar good job if he leaves Amgen Pharma and goes to those companies outside for an interview.

In addition, he even had a little hope that Abel would succeed. If the research on granulocyte therapeutics is really successful, Amgen Pharmaceutical, a small company that has almost gone bankrupt several times, will usher in a stout cash cow.

That's a good thing for him, the president who manages the company, and for the other shareholders.

Let's take an analogy.

For example, the absolutely impossible thing really happens, the study is resolved within a week, and the new drug is sold a month later.

So what can Amgen Pharma get? Can it get a drug with annual sales of at least $1 billion! Not counting R&D costs, the annual profit, even after paying taxes, is at least $600 million!

The profit of $600 million is almost 1.5 times the market value of Amgen Pharmaceutical. Based on the current valuation standard of the pharmaceutical industry, an annual profit of $600 million will suddenly make Amgen Pharma's valuation in the market reach more than $4 billion.

In other words, even if this impossible thing is realized, Abel holds more than 55% of the absolute controlling shares, and the other shareholders and shareholder representatives will not suffer. Their stock will also increase fivefold in a year......

If the annualized interest rate of investment is calculated, the worst investment return of these shareholders of Amgen Pharma is more than 7 or 8 times. The earliest investors, who invested $19 million in the company's founding capital in 1980, had a 10-year return on investment of more than 10 times.

No matter how you look at it, it's a big deal.